8-K
filed May 11, 2023, 7:59 PM ET
ticker CYTK
CIK 0001061983
other material
confidence high
sentiment neutral
materiality 0.15
Cytokinetics annual meeting approves all proposals including director exculpation amendments
CYTOKINETICS INC
- Three Class I directors elected: Kaye (53.7M for), Wierenga (79.0M for), Wysenski (81.9M for).
- Director exculpation amendment approved (84.1M for, 2.2M against).
- Officer exculpation amendment approved (74.0M for, 12.3M against).
- Ratified Ernst & Young as independent auditor for FY2023 (88.9M for).
- Advisory vote on exec compensation approved (83.1M for); say-on-pay frequency set to 1 year (86.0M).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation to Permit Director Exculpation at the 2023-05-10 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-05-10
Exact text from the filing
The stockholders approved the Amendment to the Company’s Amended and Restated Certificate of Incorporation to permit director exculpation.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-05-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-10
Exact text from the filing
The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Election of Three Class I Directors at the 2023-05-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-10
Exact text from the filing
The stockholders elected Edward M. Kaye, M.D., Wendell Wierenga, Ph.D. and Nancy J. Wysenski as Class I Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation to Permit the Exculpation of the Senior Officers of the Company at the 2023-05-10 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-05-10
Exact text from the filing
The stockholders approved the Amendment to the Company’s Amended and Restated Certificate of Incorporation to permit the exculpation of the senior officers of the Company.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation at the 2023-05-10 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-10
Exact text from the filing
The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2023 Annual Meeting of Shareholders.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYTOKINETICS INC shareholders approved Advisory Vote on Frequency of "Say on Pay" Proposal at the 2023-05-10 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-05-10
Exact text from the filing
The stockholders approved, on an advisory basis, 1-Year as the frequency with which the stockholders of the Company wish to have an advisory vote on the compensation of the Company’s named executive officers as disclosed pursuant to the SEC’s compensation disclosure rules (which disclosure includes the Compensation Discussion and Analysis, the related compensation tables and the narrative disclosure to those tables in the Company’s proxy statement).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.